<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Progestogens: contraceptives: parenteral; Contraception: parenteral; Medroxyprogesterone: contraception; Depo-Provera; Norethisterone enantate; Noristerat; Nexplanon; Etonogestrel: implant; Contraception: implants; Implanon" /><meta name="IX" content="Progestogens: contraceptives: parenteral; Contraception: parenteral; Medroxyprogesterone: contraception; Depo-Provera; Norethisterone enantate; Noristerat; Nexplanon; Etonogestrel: implant; Contraception: implants; Implanon" /><title>7.3.2.2 Parenteral progestogen-only contraceptives: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP4960-parenteral-progestogen-only-contraceptives.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP4960-parenteral-progestogen-only-contraceptives.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP4960-parenteral-progestogen-only-contraceptives.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4758-obstetrics-gynaecology-and-urinary-tract-disorders.htm">7 Obstetrics, gynaecology, and urinary-tract disorders</a> &gt; <a href="PHP4853-contraceptives.htm">7.3 Contraceptives</a> &gt; <a href="PHP4943-progestogen-only-contraceptives.htm">7.3.2 Progestogen-only contraceptives</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP4949-oral-progestogen-only-contraceptives.htm" title="Previous: ORAL PROGESTOGEN-ONLY CONTRACEPTIVES">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP4966-parenteral-progestogen-only-contraceptives.htm" title="Next: PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>7.3.2.2 </span>Parenteral progestogen-only contraceptives</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int664-progestogens.htm">Progestogens</a>).</p></div></div><p id="PHP4961"><strong>Medroxyprogesterone acetate</strong> (<em>Depo-Provera</em>®) is a long-acting progestogen given by intramuscular injection; it is as effective as the combined oral preparations but because of its prolonged action it should never be given without <em>full counselling backed by the patient information leaflet</em>. It may be used as a short-term or long-term contraceptive for women who have been counselled about the likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility. Troublesome bleeding has been reported in patients given medroxyprogesterone acetate in the immediate puerperium; delaying the first injection until 6 weeks after birth may minimise bleeding problems. If the woman is not breast-feeding, the first injection may be given within 5 days postpartum (she should be warned that the risk of heavy or prolonged bleeding may be increased). The manufacturer advises that in women who are breast-feeding, the first dose should be delayed until 6 weeks after birth; however, evidence suggests no harmful effect to infant if given earlier. The benefits of using medroxyprogesterone acetate in breast-feeding women outweigh any risks.</p> <p>Reduction in bone mineral density and, rarely, osteoporosis and osteoporotic fractures have also been reported with medroxyprogesterone acetate. The reduction in bone mineral density occurs in the first 2–3 years of use and then stabilises. See also below. </p> <div class="cI"><ul><li><p>In adolescents, medroxyprogesterone acetate (<em>Depo-Provera</em>®) should be used only when other methods of contraception are inappropriate;</p> </li><li><p> in all women, the benefits of using medroxyprogesterone acetate beyond 2 years should be evaluated against the risks;</p> </li><li><p>in women with risk factors for osteoporosis, a method of contraception other than medroxyprogesterone acetate should be considered.</p> </li></ul></div> <p id="PHP4963"><strong>Norethisterone enantate</strong> (<em>Noristerat</em>®) is a long-acting progestogen given as an oily injection which provides contraception for 8 weeks; it is used as short-term interim contraception e.g. before vasectomy becomes effective. </p> <p id="PHP4964"> An <strong>etonogestrel-releasing implant</strong> (<em>Nexplanon</em>®) is also available. It is a highly effective long-acting contraceptive, consisting of a single flexible rod that is inserted subdermally into the lower surface of the upper arm and provides contraception for up to 3 years. The manufacturer advises that in heavier women, blood-etonogestrel concentrations are lower and therefore the implant may not provide effective contraception during the third year; they advise that earlier replacement may be considered in such patients—however, evidence to support this recommendation is lacking. Local reactions such as bruising and itching can occur at the insertion site. The contraceptive effect of etonogestrel is rapidly reversed on removal of the implant. <em>The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet</em>.</p> <p><em>Implanon</em>®, also an etonogestrel-releasing implant, has been discontinued (October 2010), but some women may have the implant in place until 2013.</p> <div><h2>Cautions, contra-indications, and side-effects</h2><p>The <a title="target-block: Oral progestogen-only contraceptives cautions" href="PHP4949-oral-progestogen-only-contraceptives.htm#PHP4950">cautions</a>, <a title="target-block: Oral progestogen-only contraceptives contra-indications" href="PHP4949-oral-progestogen-only-contraceptives.htm#PHP4951">contra-indications</a>, and <a title="target-block: Oral progestogen-only contraceptives side-effects" href="PHP4949-oral-progestogen-only-contraceptives.htm#PHP4953">side-effects</a> of oral progestogen-only contraceptives apply to parenteral progestogen-only contraceptives, except that parenteral preparations reliably inhibit ovulation and therefore protect against ectopic pregnancy and functional ovarian cysts.</p></div> <div id="PHP4965"><h2>Interactions</h2><p>Effectiveness of parenteral progestogen-only contraceptives is not affected by antibacterials that do not induce liver enzymes. The effectiveness of norethisterone and medroxyprogesterone acetate intramuscular injections is not affected by enzyme-inducing drugs and they may be continued as normal during courses of these drugs. However, effectiveness of the etonogestrel-releasing implant may be reduced by enzyme-inducing drugs and an alternative contraceptive method, unaffected by the interacting drug, is recommended during treatment with the enzyme-inducing drug and for at least 4 weeks after stopping. For a short course of an enzyme-inducing drug, if a change in contraceptive method is undesirable or inappropriate, the implant may be continued in combination with additional contraceptive precautions (e.g. condom) for the duration of treatment with the enzyme-inducing drug and for 4 weeks after stopping it.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP4966-parenteral-progestogen-only-contraceptives"><a href="PHP4966-parenteral-progestogen-only-contraceptives.htm" title="PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES">PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP4949-oral-progestogen-only-contraceptives.htm">Previous: ORAL PROGESTOGEN-ONLY CONTRACEPTIVES</a> | <a class="top" href="PHP4960-parenteral-progestogen-only-contraceptives.htm#">Top</a> | <a accesskey="]" href="PHP4966-parenteral-progestogen-only-contraceptives.htm">Next: PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>